Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Plus S-1 vs S-1 in Advanced Esophageal Squamous Cell Carcinoma
NCT02319187Phase 3Unknown
- Sponsor
- Chinese Academy of Medical Sciences
- Start
- Dec 2014
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Chinese Academy of Medical Sciences. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
irinotecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT02319187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319187.